A open label, observational, multicenter, prospective, post marketing surveillance study (PMS) to evaluate safety and efficacy of sulbactomax (FDC of Ceftriaxone + Sulbactam) in patients with various bacterial infections

Trial Profile

A open label, observational, multicenter, prospective, post marketing surveillance study (PMS) to evaluate safety and efficacy of sulbactomax (FDC of Ceftriaxone + Sulbactam) in patients with various bacterial infections

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Ceftriaxone/sulbactam (Primary)
  • Indications Bacterial meningitis; Bone and joint infections; Enteric fever; Gonorrhoea; Otitis media; Postoperative infections; Respiratory tract disorders; Sepsis; Skin and soft tissue infections; Urinary tract infections
  • Focus Adverse reactions
  • Sponsors Venus Remedies
  • Most Recent Events

    • 14 May 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top